Table 5 Summary of adverse events (intent-to-treat population)
Placebo | 25 mg | 50 mg | 100 mg | 200 mg | |
|---|---|---|---|---|---|
(n = 77) | (n = 80) | (n = 79) | (n = 80) | (n = 79) | |
Patients with adverse events, number (percentage) | 52 (68%) | 51 (64%) | 51 (65%) | 62 (78%) | 62 (78%) |
Patients who withdrew, number (percentage) | 8 (10%) | 15 (19%) | 13 (16%) | 16 (20%) | 60a (76%) |
Patients with serious adverse events, number (percentage) | 8 (10%) | 7 (9%) | 12 (15%) | 10 (13%) | 17 (22%) |
Patients who died, number (percentage) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (1%) | 1 (1%) |